The 90 patients that you are talking about was the minimum enrollment for the trial. If, after the first 90 patients are evaluated, the results look promising but the primary endpoint has not been met, they can continue the trial with additional patients. I think the next review if necessary, is after an additional 40 patients. Therefore, they have multiple opportunities to meet the primary endpoint. They were so close in meeting the primary endpoint in the original Phase 3 trial and with a better trial design in the current trial, IMO, they have a high probability of meeting the primary endpoint in this trial.